Overview

Selected References for Chemokine-Based Therapeutics (2002-2007)

CCFA National Research and Clinical Conference, 6th Annual Advances in the Inflammatory Bowel Diseases, Dec 6-9, 2007, Aventura, Florida.
Bekker P et al. Inflammatory Bowel Diseases 2007; 14 (suppl.):S11 (abstract P-003)

15th United European Gastroenterology Week meeting, Oct 27-31, 2007, Paris, France.
Bekker P et al. Gut 2007; 39 (suppl. I):A23 (abstract OP-G-106)

Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Nat. AS, 2007 104:15735-15740

Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Lober R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/ SDF-1 in prostate cancer. J. Biol. Chem. 2007 doi:10.1074/jbc.M707465200

Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, Pabst O, F?rster R. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci U S A. 2007:104(15):6347-52

14th United European Gastroenterology Week meeting, Oct 21-25, 2006, Berlin, Germany.
Keshav S et al. Gut 2006; 38 (suppl. II):A22 (abstract OP-G-91)

Burns JM, Summers BC, Wang Yu, Melikian A, Berahovich R, Miao Z, Penfold MET, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Ex. Med. 2006 203(9): 2201-2213

Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, Camps M, Wells TN, Schwarz MK, Proudfoot AE, Rommel C. Chemokine inhibition--why, when, where, which and how? Biochem Soc Trans. 2004 32(Pt 2):366-77.

Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem. 2004 4(9):883-93.

Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer. 2004 4(11):901-9.

Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004 14(3):181-5.

Howard OM, Galligan CL. An expanding appreciation of the role chemokine receptors play in cancer progression. Curr Pharm Des. 2004 10(19):2377-89.

Gladue RP, Zwillich SH, Clucas AT, Brown MF. CCR1 antagonists for the treatment of autoimmune diseases. Curr Opin Investig Drugs. 2004 5(5):499-504.

Homey B. Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy. 2004 3(2):169-74.

Shadidi KR. New drug targets in rheumatoid arthritis: focus on chemokines. BioDrugs. 2004 18(3):181-7.

Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des. 2004 10(11):1245-59.

Houshmand P, Zlotnik A. Therapeutic applications in the chemokine superfamily. Curr Opin Chem Biol. 2003 7(4):457-60.

Lloyd CM, Rankin SM. Chemokines in allergic airway disease. Curr Opin Pharmacol. 2003 3(4):443-8.

Kelley VR, Rovin BH. Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol. 2003 24(4):411-21.

Proudfoot AE, Power CA, Rommel C, Wells TN. Strategies for chemokine antagonists as therapeutics. Semin Immunol. 2003 15(1):57-65.

Ikeda U. Inflammation and coronary artery disease. Curr Vasc Pharmacol. 2003 Mar;1(1):65-70.

Dowsland MH, Harvey JR, Lennard TW, Kirby JA, Ali S. Chemokines and breast cancer: a gateway to revolutionary targeted cancer treatments? Curr Med Chem. 2003 10(7):579-92.

Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. 2002 23(10):459-67.

Ajuebor MN, Swain MG, Perretti M. Chemokines as novel therapeutic targets in inflammatory diseases. Biochem Pharmacol. 2002 63(7):1191-6.

Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002 2(2):106-15.

Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov. 2002 1(5):347-58.

^ Return to Top